KR20090039735A - 프로스타글란딘 d2 수용체 길항제로서의 2-페닐-인돌 - Google Patents

프로스타글란딘 d2 수용체 길항제로서의 2-페닐-인돌 Download PDF

Info

Publication number
KR20090039735A
KR20090039735A KR1020097001687A KR20097001687A KR20090039735A KR 20090039735 A KR20090039735 A KR 20090039735A KR 1020097001687 A KR1020097001687 A KR 1020097001687A KR 20097001687 A KR20097001687 A KR 20097001687A KR 20090039735 A KR20090039735 A KR 20090039735A
Authority
KR
South Korea
Prior art keywords
chloro
phenyl
indol
pharmaceutically acceptable
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097001687A
Other languages
English (en)
Korean (ko)
Inventor
짜오시아 양
슈테판 라일링
테디어스 알. 니두작
로즈 엠. 매튜
샤론 잭슨
케이쓰 제이. 해리스
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20090039735A publication Critical patent/KR20090039735A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
KR1020097001687A 2006-07-25 2007-07-20 프로스타글란딘 d2 수용체 길항제로서의 2-페닐-인돌 Abandoned KR20090039735A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US82029906P 2006-07-25 2006-07-25
US82030106P 2006-07-25 2006-07-25
US82030206P 2006-07-25 2006-07-25
US60/820,301 2006-07-25
US60/820,302 2006-07-25
US60/820,299 2006-07-25

Publications (1)

Publication Number Publication Date
KR20090039735A true KR20090039735A (ko) 2009-04-22

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001687A Abandoned KR20090039735A (ko) 2006-07-25 2007-07-20 프로스타글란딘 d2 수용체 길항제로서의 2-페닐-인돌

Country Status (25)

Country Link
US (1) US20090176804A1 (cg-RX-API-DMAC7.html)
EP (1) EP2066628B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009544721A (cg-RX-API-DMAC7.html)
KR (1) KR20090039735A (cg-RX-API-DMAC7.html)
AR (1) AR062051A1 (cg-RX-API-DMAC7.html)
AT (1) ATE485270T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007276885A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714554A2 (cg-RX-API-DMAC7.html)
CA (1) CA2659055A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO6190511A2 (cg-RX-API-DMAC7.html)
CR (1) CR10577A (cg-RX-API-DMAC7.html)
DE (1) DE602007010010D1 (cg-RX-API-DMAC7.html)
DK (1) DK2066628T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP099087A (cg-RX-API-DMAC7.html)
GT (1) GT200900016A (cg-RX-API-DMAC7.html)
IL (1) IL196587A0 (cg-RX-API-DMAC7.html)
MA (1) MA30643B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009000830A (cg-RX-API-DMAC7.html)
NO (1) NO20090862L (cg-RX-API-DMAC7.html)
PE (1) PE20080549A1 (cg-RX-API-DMAC7.html)
PT (1) PT2066628E (cg-RX-API-DMAC7.html)
TN (1) TNSN08515A1 (cg-RX-API-DMAC7.html)
TW (1) TW200821286A (cg-RX-API-DMAC7.html)
WO (1) WO2008014186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009072576A1 (ja) * 2007-12-04 2009-06-11 Sapporo Breweries Limited 骨形成促進剤
RS52809B (sr) * 2008-11-17 2013-10-31 F. Hoffmann-La Roche Ag. Naftilsirćetne kiseline
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
PH12016501764B1 (en) 2014-03-17 2024-05-17 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
CN112384497A (zh) 2018-05-09 2021-02-19 格卢科克斯生物科技有限公司 具有选择性nox抑制活性的新型磺酰胺衍生物
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Also Published As

Publication number Publication date
PE20080549A1 (es) 2008-06-20
ECSP099087A (es) 2009-02-27
CR10577A (es) 2009-03-20
WO2008014186A1 (en) 2008-01-31
PT2066628E (pt) 2010-12-31
TNSN08515A1 (en) 2010-04-14
DE602007010010D1 (de) 2010-12-02
JP2009544721A (ja) 2009-12-17
CL2007002163A1 (es) 2008-02-08
EP2066628B1 (en) 2010-10-20
BRPI0714554A2 (pt) 2013-05-07
IL196587A0 (en) 2009-11-18
MA30643B1 (fr) 2009-08-03
CA2659055A1 (en) 2008-01-31
ATE485270T1 (de) 2010-11-15
TW200821286A (en) 2008-05-16
EP2066628A1 (en) 2009-06-10
MX2009000830A (es) 2009-02-03
AU2007276885A1 (en) 2008-01-31
DK2066628T3 (da) 2011-02-07
CO6190511A2 (es) 2010-08-19
US20090176804A1 (en) 2009-07-09
GT200900016A (es) 2010-10-13
NO20090862L (no) 2009-02-24
AR062051A1 (es) 2008-08-10

Similar Documents

Publication Publication Date Title
EP2066628B1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
KR20080108287A (ko) 프로스타글란딘 d2 수용체 길항제로서 2,6-이치환-4-일치환된 아미노-피리미딘
US20070265278A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
EP1937652B1 (en) Pyrimidine amide compounds as pgds inhibitors
RU2464262C2 (ru) Пиримидингидразидные соединения как ингибиторы pgds
CN104284657A (zh) 用于抑制RORγ活性和治疗疾病的双环砜化合物
US20110172263A1 (en) Indole derivatives as crth2 receptor antagonists
KR101365480B1 (ko) 프로스타글란딘 d2 수용체 길항제의 인산이수소염
CA2793223A1 (en) Substituted pyrimidines as prostaglandin d2 receptor antagonists
JP2010532748A (ja) カルシウムチャネル遮断薬としての2−置換インドール誘導体
AU2006237365B2 (en) 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
WO2018222917A1 (en) Ire1 small molecule inhibitors
TW200927729A (en) 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
MXPA02005231A (es) Derivados de pirimidina como inhibidores selectivos de cox-2.
US20130005741A1 (en) Substituted pyrimidine as a prostaglandin d2 receptor antagonist
ES2352725T3 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
HK1110869A (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
HK1131975B (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090123

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090219

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110114

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20111022

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee